SeaStar Medical Faces 45% Stock Drop Amid Funding Moves

Introduction

SeaStar Medical Holding Corp (NASDAQ: ICU) is a commercial-stage healthcare company specializing in extracorporeal therapies aimed at modulating hyperinflammation in critically ill patients. The company’s primary product, QUELIMMUNE (SCD-PED), received U.S. Food and Drug Administration (FDA) approval in 2024 for the treatment of acute kidney injury (AKI) related to sepsis or septic-like conditions in pediatric ICU patients. As of June 20, 2025, ICU shares closed at $0.5286, reflecting a 45.86% decline for the day, with a trading volume of 658,508 shares on NASDAQ.

Corporate Structure and Experience

Founded in 2018, SeaStar Medical operates with a small team of approximately 2–10 employees, which is characteristic of a startup environment. Led by CEO Eric Schlorff, the company has established collaborations with the Geneva Foundation’s AREVA Institute and has secured grants from the U.S. Department of Defense. The leadership team possesses experience in medical device innovation, regulatory affairs, and commercial operations relevant to the advancement of its Selective Cytopheretic Device (SCD) platform.

Recent Developments and News

On January 27, 2025, SeaStar announced the shipment of QUELIMMUNE to a California pediatric research center, marking its fifth hospital partnership. This expansion follows FDA approval under a Humanitarian Device Exemption for children weighing 10 kg or more. On January 31, 2025, the company entered into a registered direct offering agreement to sell 3,529,412 common shares (or pre-funded warrants) along with detachable warrants at a combined price of $1.70 per share, with expected gross proceeds of approximately $6 million. H.C. Wainwright & Co. served as the financial advisor for this offering, which is anticipated to close on or about February 3, 2025.

In mid-June 2025, SeaStar filed its initial S-1 registration statement on June 16 and an amendment (S-1/A) on June 20, 2025. These filings outlined the company's plans for capital raising, including risk factors and strategic initiatives, aimed at attracting institutional investors ahead of potential equity offerings.

Financial and Strategic Analysis

As of June 20, 2025, SeaStar’s market capitalization was approximately $5.18 million, based on 10.59 million shares outstanding. Key trailing twelve-month (TTM) metrics reported by CNBC include revenue of $428,000 and a gross margin of 100%. The company reported a net margin of –3,716%, an earnings per share (EPS) of –3.46, and a price-to-earnings (P/E) ratio of –0.14. SeaStar’s debt-to-equity ratio is 64.25%, with cash proceeds from the recent equity offering intended for working capital and capital expenditures.

SeaStar’s SCD platform has received six FDA Breakthrough Device Designations for various indications, including adult AKI requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome, hepatorenal syndrome, and chronic dialysis. The company is conducting a pivotal trial of SCD therapy in adult patients with AKI, targeting over 200,000 adults in the U.S. annually who lack approved immunomodulatory treatment. Outcomes from this trial could contribute to establishing SCD as a treatment option, with implications for reducing ICU stays and dialysis dependency.

Market Position and Industry Context

SeaStar Medical operates within the extracorporeal therapy market, competing against conventional dialysis and emerging immunomodulatory devices. While several blood-purification technologies exist, there are currently no FDA-approved therapies specifically designed to address the dysregulated hyperinflammatory response often seen in critically ill patients. QUELIMMUNE’s pediatric indication and the ongoing adult SCD trial address significant unmet medical needs, facilitating integration with existing hemodialysis and CRRT systems. Institutional interest is noted with over a dozen hospitals submitting Institutional Review Board (IRB) applications, with seven advancing toward approval for pediatric use.

TL;DR

SeaStar Medical’s stock fell 45.86% to $0.5286 on June 20, 2025. On January 27, the company enhanced its pediatric outreach by distributing QUELIMMUNE to a fifth hospital and secured an anticipated $6 million via a registered direct offering on January 31. SEC filings on June 16 and June 20 detail capital-raising plans and risk disclosures ahead of future funding. An ongoing pivotal trial of SCD therapy in AKI patients aims to address a significant gap in hyperinflammation management. Upcoming milestones include trial results, additional hospital partnerships, and implementation of new funding.